AUTHOR INDEX

Adjepon-Yamoah, K.K., Al-Homrany, M., Bahar, Y. & El-Bagir K. Ahmed, M. Aminoglycoside usage and monitoring in a Saudi Arabian teaching hospital: a ten-year laboratory audit, 303
Ahmadi-Abhari, S.A. *see* Akhondzadeh, S.
Airaksinen, M. *see* Nähri, U.
Akhondzadeh, S., Ahmadi-Abhari, S.A., Assadi, S.M., Shabestari, O.L., Kashani, A.R. & Farzanehgan, Z.M. Double-blind randomized controlled trial of baclofen versus clonidine in the treatment of opiates withdrawal, 347
Akhondzadeh, S., Shasavand, E., Jamilian, H.-R., Shabestari, O. & Kamalipour, A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions, 131
Al Bahrani, I. *see* Deleu, D.
Al-Eidan, F.A., McElnay, J.C., Scott, M.G. & Kearney, M.P. *Clostridium difficile*-associated diarrhoea in hospitalised patients, 101
Al-Homrany, M. *see* Adjepon-Yamoah, K.K.
Almeida, A.M. *see* Falcão, A.C.
Armstrong, D. *see* Ashworth, M.
Ashcroft, D.M, Li Wan Po, A. & Griffiths, C.E.M. Therapeutic strategies for psoriasis, 1
Ashworth, M., Armstrong, D., Colwill, S., Cohen, A. & Balazs, J. Motivating general practitioners to change their prescribing: the incentive of working together, 119
Assadi, S.M. *see* Akhondzadeh, S.
Avery, A.J. *see* Franke, L.
Axworthy, S. & Gardner, D. Aminoglycoside dosing in diabetes, 81

Bahar, Y. *see* Adjepon-Yamoah, K.K.
Balazs, J. *see* Ashworth, M.
Barber, N. *see* Stevenson, F.A.
Barry, C.A. *see* Stevenson, F.A.
Betz, C., Mihalic, D., Pinto, M.E. & Raffa, R.B. Could a common biochemical mechanism underlie addictions?, 11
Bleasel, M.D. *see* Hougardy, D.M.C.
Bleasel, M.D. *see* Naunton, M.
Bown Luzier, A. *see* Ditusa, L.
Boyer, P., Tassin, J.P., Falissart, B. & Troy, S. Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression, 363
Bradley, C.P. *see* Stevenson, F.A.
Britten, N. *see* Stevenson, F.A.
Bruckert, E. *see* Kiortsis, D.N.

Caldwell, N.A. *see* Sexton, J.
Çalis, S. *see* Dogru, S.T.
Cantrill, J.A. Measuring the appropriateness of long-term prescribing in United Kingdom general practice – is the British National Formulary the 'Gold Standard'?, 341
Caramona, M.M. *see* Falcão, A.C.
Chan, S.Y. *see* Lin, H.S.
Chean, C.S. *see* Lin, H.S.
Chen, L.C., Chen, Y.C., Yang, L.L., Chou, M.H. & Lin, M.F. Drug utilization pattern of antiepileptic drugs and traditional Chinese medicines in a general hospital in Taiwan – a pharmaco-epidemiologic study, 125
Chen, L.C., Chou, M.H., Lin, M.F. & Yang, L.L. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers, 453
Chen, Y.C. *see* Chen, L.C.
Chou, M.H. *see* Chen, L.C.
Christensen, J.D. *see* Moesby, L.
Ciesielska-Kopacz, N. *see* Kajdaniuk, D.
Ciesielska-Kopacz, N. *see* Kos-Kudła, B.
Cohen, A. *see* Ashworth, M.
Colwill, S. *see* Ashworth, M.

Damczyk, M.P. & Gardner, D.M. Risk of hormone replacement therapy in stroke patients, 239
De Oliveira, I.R. *see* Poolsup, N.
Debroe, S. *see* Hewitson, P.
Deleu, D., Louon, A., Sivagnanam, S., Sundaram, K., Okereke, P., Gravell, D., Saud Al-Salmy, H., Al Bahrani, I., Nam, D., Knox-Macaulay, H. & Hanssens, Y. Long-term effects of nitrous oxide anaesthesia on laboratory and clinical parameters in elderly Omani patients: a randomised double-blind study, 271
Dillard, R. *see* Porcelli, P.J.
Ditusa, L. & Bown Luzier, A. Potential interaction between troglitazone and atorvastatin, 279
Dogru, S.T., Çalis, S. & Öner, F. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: *in vitro-in vivo* evaluation, 427
Dunn, A.B. *see* Reddy, P.

El-Bagir K. Ahmed, M. *see* Adjepon-Yamoah, K.K.
Erlund, H. *see* Nähri, U.
Erwander, I. *see* Ramström, H.
Escario, J.A. *see* Martínez-Diaz, R.A.

Falcão, A.C., Rocha, M.J., Almeida, A.M. & Caramona, M.M. Theophylline pharmacokinetics with concomitant steroid and gold therapy, 191
Falconer, C.L. & Gardner, D.M. Treatment of acute otitis media in patients with a reported penicillin allergy, 161
Falissart, B. *see* Boyer, P.
Farzanehgan, Z.M. *see* Akhondzadeh, S.
Franke, L., Avery, A.J., Groom, L. & Horsfield, P. Is there a role for computerized decision support for drug dosing in general practice? A questionnaire survey, 373
Friesen, W.T. *see* McNamara, K.S.

© 2000 Blackwell Science Ltd

Gardner, D. *see* Axworthy, S.
Gardner, D. New series – Evidence-Based Pharmacotherapy: case reports, 77
Gardner, D.M. *see* Damczyk, M.P.
Gardner, D.M. *see* Falconer, C.L.
Gascón, A. *see* Zabala López, S.
Gill, P.S. New Series – Research Notes. The methodology of prescribing research, 315
Giral, P. *see* Kiortsis, D.N.
Glogowska-Szelag, J. *see* Kajdaniuk, D.
Gómez Barrio, A. *see* Martínez-Diaz, R.A.
Gräser, T. *see* Seeger, H.
Gravell, D. *see* Deleu, D.
Green, C.F. *see* Sexton, J.
Green, C.F., Mottram, D.R., Rowe, P.H. & Pirmohamed, M. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study, 355
Greenfield, S.M. *see* Innes, M.A.
Griffiths, C.E.M. *see* Ashcroft, D.M.
Groom, L. *see* Franke, L.

Hansen, E.W. *see* Moesby, L.
Hanssens, Y. *see* Deleu, D.
Hekster, Y.A. *see* Van Weel-Baumgarten, E.M.
Hewitson, P., Debroe, S., McBride, A. & Milne, R. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications, 295
Ho, P.C. *see* Lin, H.S.
Ho, Y.J. *see* Sexton, J.
Holden, J. & Holden, K. Comparative effectiveness of general practitioner versus pharmacist dosing of patients requiring anticoagulation in the community, 49
Holden, K. *see* Holden, J.
Holden, K. *see* Weatherhead, S.
Holmes, A. *see* Weatherhead, S.
Horsfield, P. *see* Franke, L.
Hougardy, D.M.C., Peterson, G.M., Bleasel, M.D. & Randall, C.T.C. Is enough attention being given to the adverse effects of corticosteroid therapy?, 227
Hunton, M. *see* Innes, M.A.
Hussein, A. *see* Ismail, R.

Innes, M.A., Greenfield, S.M. & Hunton, M. Using case studies for prescribing research – an example from homoeopathic prescribing, 399
Inomata, S. *see* Tanaka, E.
Ismail, R., Hussein, A., Teh, L.K. & Nizam Isa, M. CYP2D6 phenotypes among Malays in Malaysia, 379

Jamilian, H.-R. *see* Akhondzadeh, S.

Kajdaniuk, D. *see* Kos-Kudła, B.
Kajdaniuk, D. & Marek, B. Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients, 67
Kajdaniuk, D., Marek, B., Swietochowska, E., Ostrowska, Z., Glogowska-Szelag, J., Kos-Kudła, B., Ciesielska-Kopacz, N. & Wielkoszysi, T. Plasma transforming growth factor $\beta 1$ in breast cancer patients treated with CMF chemotherapy, 291
Kamalipour, A. *see* Akhondzadeh, S.
Kashani, A.R. *see* Akhondzadeh, S.
Kearney, M.P. *see* Al-Eidan, F.A.
Kendall, M.J. *see* Langford, N.J.
Kendall, M.J. *see* Nuttall, S.L.
Kendall, M.J. *see* Sapey, E.
Kiortsis, D.N., Giral, P., Bruckert, E. & Turpin, G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients, 445
Knight, T.L. *see* Poolsup, N.
Knox-Macaulay, H. *see* Deleu, D.
Kornfält, R. *see* Ramström, H.
Kos-Kudła, B. *see* Kajdaniuk, D.
Kos-Kudła, B., Ostrowska, Z., Marek, B., Ciesielska-Kopacz, N., Siemińska, L., Kajdaniuk, D., Nowak, M. & Kudla, M. Hormone replacement therapy in postmenopausal asthmatic women, 461
Kudla, M. *see* Kos-Kudła, B.

Langford, N.J. *see* Nuttall, S.L.
Langford, N.J. *see* Sapey, E.
Langford, N.J. & Kendall, M.J. Pulmonary heart disease – the need for evidence-based management, 157
Lerkiatbundit, S. & Reanmongkol, W. Use of 0.75 mg Levonorgestrel for postcoital contraception in Thailand, 185
Li Wan Po, A. *see* Ashcroft, D.M.
Li Wan Po, A. *see* Poolsup, N.
Lin, H.S., Chean, C.S., Ng, Y.Y., Chan, S.Y. & Ho, P.C. Hydroxypropyl-β-cyclodextrin increases aqueous solubility and photostability of all-*trans*-retinoic acid, 265
Lin, M.F. *see* Chen, L.C.
Louon, A. *see* Deleu, D.
Lüdtke, R. *see* Seeger, H.

Mared, L. *see* Ramström, H.
Marek, B. *see* Kajdaniuk, D.
Marek, B. *see* Kos-Kudła, B.
Martínez-Diaz, R.A., Escario, J.A., Nogal Ruiz, J.J. & Gómez Barrio, A. Evaluation of drug activity against intracellular form of *Trypanosoma cruzi* employing enzyme immunoassay, 43
May, D.B. *see* Smith, P.F.
McBride, A. *see* Hewitson, P.
McElnay, J.C. *see* Al-Eidan, F.A.
McNamara, K.S., Peterson, G.M. & Friesen, W.T. Changes in the management of acute myocardial infarction in Southern Tasmania, 111
Meadowcroft, A.M. *see* Smith, P.F.
Mihalic, D. *see* Betz, C.
Milne, R. *see* Hewitson, P.
Misawa, S. *see* Tanaka, E.
Mishra, V. *see* Vyas, S.P.
Moesby, L., Hansen, E.W. & Christensen, J.D. Endotoxin testing of proteins for parenteral administration using the Mono Mac 6 assay, 283
Mottram, D.R. *see* Green, C.F.

Moyna, N.M. *see* Reddy, P.
Mueck, A.O. *see* Seeger, H.

Nähri, U., Airaksinen, M., Tanskanen, P. & Erlund, H. Therapeutic outcomes monitoring by community pharmacists can improve clinical outcomes in asthma treatment, 177
Nam, D. *see* Deleu, D.
Naunton, M., Peterson, G.M. & Bleasel, M.D. Overuse of proton pump inhibitors, 333
Ng, Y.Y. *see* Lin, H.S.
Nizam Isa, M. *see* Ismail, R.
Nogal Ruiz, J.J. *see* Martínez-Diaz, R.A.
Nowak, M. *see* Kos-Kudła, B.
Nuttall, S.L., Langford, N.J. & Kendall, M.J. Beta-blockers in heart failure. 1. Clinical evidence, 395

O'Shea, T.M. *see* Porcelli, P.J.
Okereke, P. *see* Deleu, D.
Öner, F. *see* Dogru, S.T.
Ostrowska, Z. *see* Kajdaniuk, D.
Ostrowska, Z. *see* Kos-Kudła, B.

Peterson, G.M. *see* Hougardy, D.M.C.
Peterson, G.M. *see* McNamara, K.S.
Peterson, G.M. *see* Naunton, M.
Pina, M.A. *see* Zabala López, S.
Pinto, M.E. *see* Betz, C.
Pirmohamed, M. *see* Green, C.F.
Poolsup, N., Li Wan Po, A. & De Oliveira, I.R. Systematic overview of lithium treatment in acute mania, 139
Poolsup, N., Li Wan Po, A. & Knight, T.L. Pharmacogenetics and psychopharmacotherapy, 197
Porcelli, P.J., O'shea, T.M. & Dillard, R. A linear regression model to predict the pH of neonatal parenteral nutrition solution, 55

Raffa, R.B. *see* Betz, C.
Ramström, H., Erwander, I., Mared, L., Kornfält, R. & Seiving, B. Pharmaceutical intervention in the care of cystic fibrosis patients, 437
Randall, C.T.C. *see* Hougardy, D.M.C.
Reanmongkol, W. *see* Lerkiatbundit, S.
Reddy, P., White, C.M., Dunn, A.B., Moyna, N.M. & Thompson, P.D. The effect of testosterone on health-related quality of life in elderly males – a pilot study, 421
Ritch, A.E.S. *see* Sarkar, P.K.
Rocha, M.J. *see* Falcão, A.C.
Rowe, P.H. *see* Green, C.F.

Sapey, E., Langford, N.J. & Kendall, M.J. Inhaled corticosteroids and chronic obstructive pulmonary disease, 235
Sarkar, P.K. & Ritch, A.E.S. Management of urinary incontinence, 251
Saud Al-Salmy, H. *see* Deleu, D.
Scott, M.G. *see* Al-Eidan, F.A.
Seeger, H., Lüdtke, R., Gräser, T., Wallwiener, D. & Mueck, A.O. Effect of oral contraceptives on the urinary excretion of biochemical markers indicating vasoactive action, 221
Seiving, B. *see* Ramström, H.
Sexton, J., Ho, Y.J., Green, C.F. & Caldwell, N.A. Ensuring seamless care at hospital discharge: a national survey, 385
Shabestari, O. *see* Akhondzadeh, S.
Shasavand, E. *see* Akhondzadeh, S.
Siemińska, L. *see* Kos-Kudła, B.
Sihorkar, V. *see* Vyas, S.P.
Sivagnanam, S. *see* Deleu, D.
Smith, P.F., Meadowcroft, A.M. & May, D.B. Treating mammalian bite wounds, 85
Stevenson, F.A., Britten, N., Barry, C.A., Barber, N. & Bradley, C.P. Qualitative methods and prescribing research, 317
Sundaram, K. *see* Deleu, D.
Swietochowska, E. *see* Kajdaniuk, D.

Tanaka, E., Inomata, S. & Yasuhara, H. The clinical importance of conventional and quantitative liver function tests in liver transplantation, 411
Tanaka, E., Terada, M. & Misawa, S. Cytochrome P450 2E1: its clinical and toxicological role, 165
Tanaka, E., Yamazaki, K. & Misawa, S. Update: the clinical importance of acetaminophen hepatotoxicity in non-alcoholic and alcoholic subjects, 325
Tanskanen, P. *see* Nähri, U.
Tassin, J.P. *see* Boyer, P.
Teh, L.K. *see* Ismail, R.
Terada, M. *see* Tanaka, E.
Thompson, P.D. *see* Reddy, P.
Thomson, C. *see* Zabala López, S.
Troy, S. *see* Boyer, P.
Tully, M. The impact of information technology on the performance of clinical pharmacy services, 243
Turpin, G. *see* Kiortsis, D.N.

Valdearcos, S. *see* Zabala López, S.
Van Den Bosch, W.J. *see* Van Weel-Baumgarten, E.M.
Van Den Hoogen, H.J. *see* Van Weel-Baumgarten, E.M.
Van Weel-Baumgarten, E.M., Van Den Bosch, W.J., Hekster, Y.A., Van Den Hoogen, H.J. & Zitman, F.G. Treatment of depression related to recurrence: ten-year follow-up in General Practice, 61
Vyas, S.P., Sihorkar, V. & Mishra, V. Controlled and targeted drug delivery strategies towards intraperiodontal pocket diseases – an overview, 21

Wallwiener, D. *see* Seeger, H.
Weatherhead, S., Holmes, A. & Holden, K. Managed substitution of modified release nitrates with an asymmetric dosing regimen, 309
White, C.M. *see* Reddy, P.
Wielkoszysi, T. *see* Kajdaniuk, D.

Yamazaki, K. *see* Tanaka, E.
Yang, L.L. *see* Chen, L.C.
Yasuhara, H. *see* Tanaka, E.

Zabala López, S., Thomson, C., Valdearcos, S., Gascón, A. & Pina, M.A. Alfuzosin-induced hepatotoxicity, 73
Zitman, F.G. *see* Van Weel-Baumgarten, E.M.

KEYWORD INDEX

β-blockers, 111
γ-globulin, 283
2-hydroxypropyl-*β*-cyclodextrin, 265
5HT, 11

ACE inhibitors, 111, 157
Acetaminophen, 325
Acute myocardial infarction, 111
Addiction, 11
Adenosine, 131
Adherence, 445
Adverse drug reaction, 355
Adverse effects, 227
Alfuzosin, 73
Allergy, 161
All-*trans*-retinoic acid, 265
Aminoglycoside, 81, 303
Amoxicillin, 161
Anaesthetics, 271
Anhedonia, 363
Animal, 85
Anti-arrhythmics, 111
Antibiotics, 81, 85, 161, 427
Anticoagulation, 49
Anticonvulsants, 139
Antidepressants, 61
Antiepileptic drug, 125
Antihyperlipidemic drugs, 445
Antimicrobials, 21, 101
Antipsychotics, 131, 139
Anxiety, 363
Appropriateness, 341
Aqueous solubility, 265
Aspirin, 111
Asthma, 177, 191
Asymmetic dosing schedule, 309
Atorvastatin, 279

Baclofen, 347
Bacteria, 85
Beta-2 agonists, 157
BHP, 73
Biofilms, 21
Bite, 85
Bone density, 227
Bone, 55
Breast cancer, 67, 291
Bronchial asthma, 461

Calcitonin, 435
Calcium, 55
Calcium-channel antagonists, 111
Carbamazepine, 125
Cardiovascular disease, 445
Case reports, 77
Cephalosporins, 101
cGMP, 221

Chagas' disease, 43
Chemotherapy, 67, 291
Children, 161
Chinese medicine, 453
Chloroxazone, 411
Cholesterol lowering agents, 111
Cholesterol, 445
Chronic airways disease, 157
Chronic obstructive airways disease (COAD), 191
Cicardian rhythm, 461
Clinical assessment, 251
Clinical information, 77
Clinical pharmacy, 243
Clinical skill, 77
Clinidine, 347
Clonazepam, 125
Clostridium difficile, 101
Clostridium difficile-associated diarrhoea, 101
CMF, 67
Cobalamin, 271
Communication systems, 385
Compliance, 445
Computerized decision support, 373
Contraception, 185
Contraceptives, 221
Cor pulmonale, 157
Corticosteroids, 227
Cost, 119
Cross-over studies, 427
Cyclosporin, 1
CYP2D6 polymorphism, 379
CYP2E1, 165
Cystic fibrosis, 427
Cytochrome P450 2E1, 325
Cytochrome P450, 165, 197, 279, 411

Data, 77
Debrisoquine, 379
DELFIA, 283
Delivery systems, 21
Depression, 61, 363
Detrusor instability, 251
Diabetes, 81
Diagnostic approach, 251
Dipyridamole, 131
Dopamine, 11, 131
Dose, 61
Dosing, 81
Drug activity, 43
Drug interaction, 279
Drug metabolizing enzyme, 411
Drug monitoring, 303

Education, 119, 185
Efficacy, 363

Elderly, 421
Electronic patient record, 243
ELISA, 43
Enzyme induction, 279
Epilepsy, 125
Estradiol, 221
Ethanol, 325
Ethinylestradiol, 221
Ethnicity, 197
Evaluation, 333
Evidence, 77
Evidence-based pharmacotherapy, 77

Fibres, 21
Fibroblasts, 43
Folate, 271
Fractures, 227

Galactose, 411
General practice, 341, 373
General practitioners, 49, 119
Genes, 1
Genetic, 197
Gingivitis, 21
Gold, 191
Growth factor, 67

Haloperidol, 131
Health informatics, 243, 373
Hepatitis C, 11
Hepatotoxicity, 73, 325
Herbs, 125
HIV, 11
Home infusion therapy, 427
Hormone replacement therapy, 239, 461
Hormones, 67
Hospital admissions, 355
Hospital discharge, 385
Hospital stay, 101
Human albumin solution, 283
Human, 325, 411
Hypercholesterolemia, 445
Hyperglycaemia, 227

IGF-1, 67
Immunoassay, 43
Indocyanine green, 411
Infection, 21, 85
Infusion pumps, 427
INR, 49
Intercourse, 185
Interleukin-6, 283
Intrapocket, 21
Intra-venous, 271
Isoenzymes, 165

© 2000 Blackwell Science Ltd

Jaundice, 73

Labelling, 185
Leflunomide, 295
Levonorgestrel, 185
Lidocaine, 411
Linear regression, 55
Lithium, 139
Liver function, 411
Liver transplantation, 411
Liver, 73, 165

Malays, 379
Mania, 139
Metabolism, 165, 197
Methotrexate, 1
Midazolam, 411
Monitoring, 49
Monoethylglycinexylidide, 411
Mortality, 101

Nephrotoxicity, 81
Nitrates, 111
Nitrous oxide, 271
Non-compliance, 445

Observational studies, 317
Oestradiol, 461
Oestrone, 461
Opiate withdrawal, 347
Opioid receptor, 11
Oral emulsion, 435
Oral nitrates, 309
Osteoporosis, 227
Otitis media, 161
Outcome, 61
Outreach service, 49
Overdose, 325
Overuse, 333

PACT, 119
Paeoniae Radix, 453
Parenteral nutrition, 55
Patient counselling, 385
Peak expiratory flow (PEF), 177
Periodontal, 21
pH, 55
Pharmaceutical care, 385
Pharmacist, 49, 177
Pharmacodynamics, 197
Pharmacogenetics, 197
Phenotype, 379
Phenytoin, 125
Phosphorous, 55
Photostability, 265
Phototherapy, 1
Polymorphism, 165, 197
Prednisolone, 227
Prescribing research, 315, 317
Prescribing, 119, 341, 373
Prescriptions, 61
Primary care groups, 119
Progestin, 221
Propofol, 271
Prospective studies, 427
Prostacyclin, 221
Protease inhibitor, 435
Proton pump inhibitors, 333
Pseudomembranous colitis, 101
Psoriasis, 1
Psychopharmacology, 197
Psychotropics, 61
Pulmonary heart failure, 157
Pyrogens, 283

Qualitative methods, 317
Quality of life, 421, 427
Quality, 119

Rat model, 435
Receptors, 131
Recurrence, 61
Relaxin, 221
Research methods, 315, 317
Response, 139
Review, 333
Rheumatoid arthritis, 295

Safety, 333
Saudi Arabia, 303
Schizophrenia, 131
Screening, 43
Seamless care, 385
Seizures, 125
Self-management, 177
Sequential improvement, 363
Sertraline, 363
Somatropin, 283
Steroids, 177
Stress incontinence, 251
Stroke, 239
Substrate, 165
Sulphamethoxazole, 161
Susceptibility, 85
Symptoms, 139
Systematic review, 295

T-cells, 1
Testosterone, 421
TGFβ, 291
Theophylline, 191
Therapeutic drug monitoring (TDM), 191
Therapeutic outcomes monitoring (TOM), 177
Therapeutic substitution, 309
Therapeutic use, 325
Thrombolytic, 111
Thromboxane, 221
Topical agents, 1
Toxicological side effects, 325
Traditional Chinese medicine, 125
Treatment, 251
Trimethoprim, 161
Troglitazone, 279
Trypanosoma cruzi, 43

Urinary incontinence, 251
Urodilatin, 221

Valproate, 125
Valproic acid, 453
Vasodilators, 157
Very low birth weight infants, 55
Volatile anaesthetics, 271

Warfarin, 111
World Health Organization (WHO), 185
Wounds, 85
W/o/w emulsion, 435